摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N-二boc-2-氨基-4-溴吡啶 | 1216620-65-3

中文名称
N,N-二boc-2-氨基-4-溴吡啶
中文别名
N,N-二-BOC-2-氨基-4-溴吡啶
英文名称
di-tert-butyl (4-bromopyridin-2-yl)iminodicarbonate
英文别名
N,N-DiBoc-2-amino-4-bromopyridine;tert-butyl N-(4-bromopyridin-2-yl)-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate
N,N-二boc-2-氨基-4-溴吡啶化学式
CAS
1216620-65-3
化学式
C15H21BrN2O4
mdl
——
分子量
373.247
InChiKey
CNKRGILVFOHONI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    414.4±55.0 °C(Predicted)
  • 密度:
    1.352±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    68.7
  • 氢给体数:
    0
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2933399090
  • 储存条件:
    2-8°C

SDS

SDS:604cc0f2e4511a9a8ff7d2e1b80c042a
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: N,N-Diboc-2-amino-4-bromopyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: N,N-Diboc-2-amino-4-bromopyridine
CAS number: 1216620-65-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H21BrN2O4
Molecular weight: 373.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    N,N-二boc-2-氨基-4-溴吡啶甲醇tris-(dibenzylideneacetone)dipalladium(0) 、 palladium on activated charcoal 、 二苯基膦叠氮化物氢气三乙胺三(邻甲基苯基)磷 、 sodium hydroxide 作用下, 以 1,4-二氧六环甲醇N,N-二甲基甲酰胺 为溶剂, 25.0~90.0 ℃ 、344.75 kPa 条件下, 反应 56.17h, 生成 4-(2-氨基乙基)吡啶-2-氨基甲酸叔丁酯
    参考文献:
    名称:
    [EN] AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF
    [FR] COMPOSÉS AMINOPYRIDINE ET PROCÉDÉS POUR LEUR PRÉPARATION ET LEUR UTILISATION
    摘要:
    本发明一般涉及治疗靶向细菌Porphyromonas gingivalis的治疗药物,包括其蛋白酶精氨酸龈蛋白酶A/B(Rgp),以及它们用于治疗与P. gingivalis感染相关的疾病,包括脑部疾病如阿尔茨海默病。在某些实施例中,本发明提供根据本文所述的Formula I和Formula III的化合物,以及其药用可接受的盐。
    公开号:
    WO2018209132A1
  • 作为产物:
    描述:
    2-氨基-4-溴吡啶二碳酸二叔丁酯4-二甲氨基吡啶 作用下, 以 二氯甲烷 为溶剂, 以81%的产率得到N,N-二boc-2-氨基-4-溴吡啶
    参考文献:
    名称:
    一种作为CDK抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
    摘要:
    本发明属于吡啶乙酰胺类衍生物技术领域,具体涉及一种作为CDK抑制剂的吡啶乙酰胺类衍生物、其制备方法及应用。所述吡啶乙酰胺类衍生物表现出优异的CDK9/CDK7酶抑制活性,可用于制备治疗癌症的药物,所述癌症尤其是血液癌,包括急性髓细胞白血病、多发性骨髓瘤、慢性淋巴细胞性白血病、滤泡性淋巴瘤等和实体瘤,包括乳腺癌、前列腺癌、卵巢癌、肝细胞癌、胰腺癌、肾癌、胃癌、结直肠癌和肺癌等的治疗。
    公开号:
    CN113173924B
点击查看最新优质反应信息

文献信息

  • SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
    申请人:Arizona Board of Regents on Behalf of the University of Arizona
    公开号:US20200039989A1
    公开(公告)日:2020-02-06
    This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.
    这项发明属于药物化学领域。具体来说,该发明涉及一类新型小分子,具有6,5-杂环结构(例如,具有咪唑吡啶咪唑嘧啶咪唑吡嗪咪唑吡啶嗪、咪唑三嗪、苯并咪唑、苯并三唑、苯并异嗪、嘌呤吲唑、三唑三嗪、三唑吡啶嗪、三唑嘧啶、三唑吡嗪、三唑四嗪、三唑吡啶吡唑吡嗪吡唑嘧啶吡唑吡啶嗪、吡唑三嗪、吡唑吡啶、异嗪吡嗪、异嗪嘧啶、异嗪吡啶嗪、异嗪三嗪、或异嗪吡啶结构),其作为DYRK1A、DYRK1B和Clk-1的抑制剂,以及它们作为治疗阿尔茨海默病、唐氏综合征、糖尿病、胶质母细胞瘤、自身免疫疾病、癌症(例如,胶质母细胞瘤、前列腺癌)、炎症性疾病(例如,气道炎症)和其他疾病的治疗药物的用途。
  • 一种作为CDK9抑制剂的多环酰胺类衍生物、其制备方法及用途
    申请人:苏州阿尔脉生物科技有限公司
    公开号:CN113149996B
    公开(公告)日:2022-12-20
    本发明属于多环酰胺类衍生物技术领域,具体涉及一种作为CDK9抑制剂的多环酰胺类衍生物、其制备方法及用途。所述多环酰胺类衍生物表现出优异的CDK9酶抑制活性,可用于制备治疗癌症的药物,所述癌症尤其是血液癌,包括急性髓细胞白血病、多发性骨髓瘤、慢性淋巴细胞性白血病、滤泡性淋巴瘤等和实体瘤,包括乳腺癌、前列腺癌、卵巢癌、肝细胞癌、胰腺癌、肾癌、胃癌、结直肠癌和肺癌等。
  • [EN] POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] DÉRIVÉ AMIDE POLYCYCLIQUE SERVANT D'INHIBITEUR DE CDK9, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种作为CDK9抑制剂的多环酰胺类衍生物、其制备方法及用途
    申请人:SUZHOU ALPHAMA BIOTECHNOLOGY CO LTD
    公开号:WO2021227904A1
    公开(公告)日:2021-11-18
    一种作为CDK9抑制剂的多环酰胺类衍生物、其制备方法及用途。所述多环酰胺类衍生物表现出优异的CDK9酶抑制活性,可用于制备治疗癌症的药物,所述癌症尤其是血液癌,包括急性髓细胞白血病、多发性骨髓瘤、慢性淋巴细胞性白血病、滤泡性淋巴瘤等和实体瘤,包括乳腺癌、前列腺癌、卵巢癌、肝细胞癌、胰腺癌、肾癌、胃癌、结直肠癌和肺癌等。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-